EVH icon

Evolent Health

10.43 USD
-0.28
2.61%
At close Feb 21, 4:00 PM EST
After hours
10.41
-0.02
0.19%
1 day
-2.61%
5 days
4.09%
1 month
2.56%
3 months
-10.01%
6 months
-62.90%
Year to date
-9.23%
1 year
-65.16%
5 years
-11.38%
10 years
-44.70%
 

About: Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.

Employees: 4,700

0
Funds holding %
of 7,139 funds
0
Analysts bullish %
of 12 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

58% more call options, than puts

Call options by funds: $20.2M | Put options by funds: $12.8M

26% more repeat investments, than reductions

Existing positions increased: 87 | Existing positions reduced: 69

8.71% less ownership

Funds ownership: 113.73% [Q3] → 105.02% (-8.71%) [Q4]

10% less funds holding

Funds holding: 260 [Q3] → 235 (-25) [Q4]

16% less first-time investments, than exits

New positions opened: 58 | Existing positions closed: 69

63% less capital invested

Capital invested by funds: $3.73B [Q3] → $1.38B (-$2.36B) [Q4]

71% less funds holding in top 10

Funds holding in top 10: 7 [Q3] → 2 (-5) [Q4]

Research analyst outlook

12 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$12
15%
upside
Avg. target
$15.08
45%
upside
High target
$18
73%
upside

12 analyst ratings

11 positive
92%
neutral
8%
negative
0%
Piper Sandler
Jessica Tassan
35% 1-year accuracy
8 / 23 met price target
53%upside
$16
Overweight
Reiterated
21 Feb 2025
Needham
Ryan MacDonald
56% 1-year accuracy
38 / 68 met price target
44%upside
$15
Buy
Reiterated
21 Feb 2025
JMP Securities
Constantine Davides
40% 1-year accuracy
12 / 30 met price target
15%upside
$12
Market Outperform
Reiterated
14 Feb 2025
JP Morgan
Anne Samuel
50% 1-year accuracy
18 / 36 met price target
25%upside
$13
Overweight
Maintained
28 Jan 2025
Oppenheimer
Jeff Jones
17% 1-year accuracy
7 / 41 met price target
73%upside
$18
Outperform
Maintained
24 Jan 2025

Financial journalist opinion

Based on 9 articles about EVH published over the past 30 days

Neutral
Seeking Alpha
1 day ago
Evolent Health, Inc. (EVH) Q4 2024 Earnings Call Transcript
Evolent Health, Inc. (NYSE:EVH ) Q4 2024 Earnings Conference Call February 20, 2025 5:00 PM ET Company Participants Seth Frank - Vice President, Investor Relations Seth Blackley - Chief Executive Officer John Johnson - Chief Financial Officer Conference Call Participants Matthew Gillmor - KeyBanc Charles Rhyee - TD Cowen Andrea Alfonso - UBS Jailendra Singh - Truist Securities Ryan Daniels - William Blair Jeff Garro – Stephens Anne Samuel - J.P. Morgan Richard Close - Canaccord Genuity Jessica Tassan - Piper Sandler David Larsen - BTIG Daniel Grosslight – Citi Matthew Shea - Needham Operator Welcome to the Evolent Earnings Conference Call for the Fourth Quarter and Year End December 31, 2024.
Evolent Health, Inc. (EVH) Q4 2024 Earnings Call Transcript
Positive
Zacks Investment Research
1 day ago
Evolent Health (EVH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Evolent Health (EVH) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Evolent Health (EVH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Neutral
Zacks Investment Research
1 day ago
Evolent Health (EVH) Reports Q4 Loss, Lags Revenue Estimates
Evolent Health (EVH) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.23 per share a year ago.
Evolent Health (EVH) Reports Q4 Loss, Lags Revenue Estimates
Neutral
PRNewsWire
1 day ago
Evolent Announces Fourth Quarter and Full Year 2024 Results
Revenue of $646.5 million for the three months ended December 31, 2024 and $2,554.7 million for the year ended December 31, 2024, representing 16.3% and 30.1% growth over 2023, respectively. Net loss attributable to common shareholders of Evolent Health, Inc. of $30.6 million for three months ended December 31, 2024 and $93.5 million for the year ended December 31, 2024, resulting in a net loss margin of (4.7)% and (3.7)%, respectively.
Evolent Announces Fourth Quarter and Full Year 2024 Results
Positive
Zacks Investment Research
4 days ago
Evolent Health (EVH) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Beyond analysts' top -and-bottom-line estimates for Evolent Health (EVH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
Evolent Health (EVH) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Negative
Zacks Investment Research
1 week ago
Earnings Preview: Evolent Health (EVH) Q4 Earnings Expected to Decline
Evolent Health (EVH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Evolent Health (EVH) Q4 Earnings Expected to Decline
Neutral
PRNewsWire
2 weeks ago
Evolent Health Announces Changes to Board of Directors
Richard " Rick "  Jelinek to Be Named Chair of the Board at 2025 Annual Meeting Company Continues Board Refreshment Efforts with Brendan Springstubb ' s Appointment as New Independent Director WASHINGTON , Feb. 4, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent"), a company focused on achieving better health outcomes for people with complex conditions, today announced changes to its Board of Directors as part of the Company's ongoing commitment to strong corporate governance and to collaboration with shareholders. Rick Jelinek, who joined the Evolent Board as an independent director in 2023, will be named Chair of the Board at the 2025 Annual Meeting, succeeding Cheryl Scott.
Evolent Health Announces Changes to Board of Directors
Negative
Zacks Investment Research
3 weeks ago
New Strong Sell Stocks for January 30th
DEC, ERO and EVH have been added to the Zacks Rank #5 (Strong Sell) List on January 30, 2024.
New Strong Sell Stocks for January 30th
Neutral
PRNewsWire
3 weeks ago
Evolent To Release Fourth Quarter 2024 Financial Results on Thursday, February 20, 2025
Company to Participate in Upcoming Conferences WASHINGTON , Jan. 27, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its fourth quarter 2024 financial results on Thursday, February 20, 2025, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com.
Evolent To Release Fourth Quarter 2024 Financial Results on Thursday, February 20, 2025
Neutral
PRNewsWire
2 months ago
Evolent announces Dr. Von Nguyen as incoming Chief Medical Officer, effective January 1
Longtime CMO Dr. Andrew Hertler to serve as senior advisor and CMO emeritus. WASHINGTON , Dec. 18, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, announced the appointment of Dr. Von Nguyen as Chief Medical Officer, effective January 1, 2025.
Evolent announces Dr. Von Nguyen as incoming Chief Medical Officer, effective January 1
Charts implemented using Lightweight Charts™